Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 13

Prospective cross-sectional multicenter study on domiciliary noninvasive ventilation in stable hypercapnic COPD patients

Authors Yazar EE, Özlü T, Sarıaydın M, Taylan M, Ekici A, Aydın D, Coşgun IG, Durmuş Koçak N

Received 2 February 2018

Accepted for publication 9 May 2018

Published 10 August 2018 Volume 2018:13 Pages 2367—2374

DOI https://doi.org/10.2147/COPD.S164384

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Charles Downs

Peer reviewer comments 3

Editor who approved publication: Dr Richard Russell


Esra Ertan Yazar,1 Tevfik Özlü,2 Muzaffer Sarıaydın,3 Mahşuk Taylan,4 Aydanur Ekici,5 Derya Aydın,6 İbrahim Güven Coşgun,7 Nagihan Durmuş Koçak8

On behalf of the COHOV Study Group

1Department of Pulmonology, Yedikule Chest Disease and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey; 2Department of Pulmonology, School of Medicine, Karadeniz Technical University, Trabzon, Turkey; 3Department of Pulmonology, School of Medicine, Afyon Kocatepe University, Afyon, Turkey; 4Department of Pulmonology, School of Medicine, Dicle University, Diyarbakır, Turkey; 5Department of Pulmonology, School of Medicine, Kırıkkale University, Kırıkkale, Turkey; 6Department of Pulmonology, Balıkesir Chest Disease Government Hospital, Balıkesir, Turkey; 7Department of Pulmonology, Afyonkarahisar Government Hospital, Afyonkarahisar, Turkey; 8Department of Pulmonology, Sureyyapasa Chest Disease and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey

Background: Domiciliary noninvasive ventilation (NIV) use in stable hypercarbic COPD is becoming increasingly widespread. However, treatment compliance criteria and factors related to compliance remain to be defined.
Methods: This research was designed as a prospective, cross-sectional, multicenter real-life study. Chronic hypercapnic COPD patients who were using domiciliary NIV for at least 1 year and being followed up in 19 centers across Turkey were included in the study. The patients who used NIV regularly, night or daytime and ≥5 hours/d, were classified as “high-compliance group,” and patients who used NIV irregularly and <5 hours/d as “low-compliance group."
Results: Two hundred and sixty-six patients with a mean age of 64.5±10.3 years were enrolled, of whom 75.2% were males. They were using domiciliary NIV for 2.8±2 years. Spontaneous time mode (p<0.001) and night use (p<0.001) were more frequent in the high-compliance group (n=163). Also, mean inspiratory positive airway pressure values of the high-compliance group were significantly higher than the low-compliance group (n=103; p<0.001). Cardiac failure (p=0.049) and obesity (p=0.01) were significantly more frequent in the high-compliance group. There were no difference between 2 groups regarding hospitalization, emergency department and intensive care unit admissions within the last year, as well as modified Medical Research Council dyspnea and COPD Assessment Test scores. With regard to NIV-related side effects, only conjunctivitis was observed more frequently in the high-compliance group (p=0.002).
Conclusion: Determination of the patients who have better compliance to domiciliary NIV in COPD may increase the success and effectiveness of treatment. This highly comprehensive study on this topic possesses importance as it suggests that patient and ventilator characteristics may be related to treatment compliance.

Keywords: COPD, noninvasive ventilation, compliance

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]